Skip to main content
EMVISION MEDICAL DEVICES LTD logo

EMVISION MEDICAL DEVICES LTD — Investor Relations & Filings

Ticker · EMV ISIN · AU0000028375 ASX Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2021-05-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX EMV

About EMVISION MEDICAL DEVICES LTD

https://emvision.com.au/

EMVision Medical Devices Ltd is a medical technology company focused on the development and commercialization of portable medical imaging devices. The company specializes in electromagnetic microwave imaging technology designed for the rapid diagnosis and monitoring of stroke and traumatic brain injury. Its primary product is a portable brain scanner intended for use at the point of care, including intensive care units, emergency departments, and ambulances. By utilizing non-ionizing radiation, the technology provides a safe, cost-effective, and mobile alternative to traditional neuroimaging modalities like CT and MRI. The device aims to facilitate earlier clinical intervention by enabling bedside assessment, potentially improving patient outcomes through faster detection of ischemic and hemorrhagic strokes.

Recent filings

Filing Released Lang Actions
Appendix 3G 15 pages 363.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX, which is a notification of the issue, conversion, or payment up of equity securities. It details the issuance of unquoted securities under an employee incentive scheme, including specifics such as the number of options issued, exercise price, expiry date, and references to the employee securities incentive plan. The document is regulatory in nature, providing detailed disclosure about securities issuance rather than a financial report or earnings announcement. It is not an annual or interim report, nor a call transcript or management report. It is a formal notification of a capital change event (issuance of new securities). Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual notification, not just an announcement of a report publication or a certification.
2021-05-05 English
Appendix 4C - quarterly 9 pages 282.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C – 31 MARCH 2021 QUARTERLY ACTIVITIES & CASHFLOW REPORT' and provides detailed quarterly updates on product development, collaborations, funding, cash flow, and operational activities for the quarter ended 31 March 2021. It includes substantive financial data such as cash reserves, operating outflows, R&D expenditure, and financing cash flows. The document is approximately 15,000 characters long, indicating it is a comprehensive report rather than a brief announcement. The content aligns with a quarterly report providing financial and operational performance for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-04-29 English
Breakthroughs in Technology & Product Development 4 pages 654.4KB
Regulatory Filings Classification · 95% confidence The document is a detailed update from EMVision Medical Devices Ltd about significant breakthroughs in their technology and product development, specifically focusing on new diagnostic techniques related to stroke care. It includes technical descriptions, clinical validation status, and forward-looking statements about the technology's potential impact. There are no financial statements, earnings data, or regulatory filings such as audit reports or certifications. The document is not a report of voting results, management changes, or legal proceedings. It is not a transcript of a call or a presentation slide deck. The content is a corporate announcement about product development progress and clinical validation, which fits best under a general regulatory announcement category rather than a formal financial or governance report. The document length is substantial (over 13,000 characters), and it provides substantive information rather than just announcing a report publication. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2021-04-27 English
Change of Director's Interest Notice 3 pages 209.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the change (on-market purchase), and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is about a director's interest change, not a full financial report or announcement of a meeting or dividend. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2021-04-14 English
EMVision presents at ASX Small and Mid-Cap Conference 16 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is a presentation given by EMVision Medical Devices Limited at the ASX Small and Midcap Conference 2021. It includes detailed information about the company's technology, clinical trial data, funding, and future plans. The text explicitly states it is a presentation and includes forward-looking statements, disclaimers, and detailed product and clinical trial information. There is no indication that this is an official financial report, earnings release, or regulatory filing. The content aligns with an investor presentation focusing on financials, strategy, and market position rather than a formal report or announcement. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-03-16 English
Successful MRFF Bid 4 pages 370.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that EMVision Medical Devices Ltd, in collaboration with the Australian Stroke Alliance, has won a Stage 2 Medical Research Future Fund (MRFF) bid. The content focuses on the funding award, the purpose of the funding, the collaboration details, and forward-looking statements about the company's plans and technology development. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no mention of a report being attached or published. The document is an announcement of a funding/grant award and collaboration, which fits best under Capital/Financing Update (CAP) as it relates to a significant non-dilutive cash funding event for the company. The document length is over 10,000 characters, so it is not a brief announcement or a report publication notice. Therefore, the most appropriate classification is CAP with high confidence.
2021-03-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.